Novavax Inc. (NVAX) fundamentals score
Novavax, Inc., together with its wholly owned subsidiaries, tackles some of the world’s most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 2.7 out of 10, Unhealthy fundamentals
- Growth: 1.2/10
- Profitability: 1.7/10
- Financial health: 3.8/10
- Earnings quality: 5.6/10
- Valuation: 2.3/10
Scores are calculated from Novavax Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10